Pharmaceutical Sector

Cipla Q1 Profit higher by 29.73%

CiplaMumbai: Drug manufacturer Cipla posted a 29.73 percent enhancement in its net earnings at Rs 119.76 crore for the quarter ended June 30 as against Rs 170.43 crore for the same period of the last year.

The company’s total income (net of excise) augmented 4.34 per cent to Rs 920.37 crore for the June quarter against Rs 882.05 crore for the quarter ended June 30, 2006.

At the board meeting, the company’s directors also recommended a dividend of Rs 2 per equity share for the year 2006-2007 amounting to Rs 155.46 crore.

Shares of Cipla last traded at Rs 200.90, down 2.21 per cent on the BSE.

Rising Markets Stimulate Ranbaxy’s Qauterly Income By 118%

Ranbaxy Laboratories Ltd.New Delhi: Actuated by maturation in key emerging markets, India’s leading pharmaceutical company Ranbaxy Laboratories’ net profit for the quarter ended June 30 climbed up 118 percent to Rs 266.2 crore from Rs 122.11 crore in the corresponding period of the last year.

The company’s business in the rising market segments developed 44 per cent in the quarter, adding as much as 54 percent to its worldwide sales.

Biocon Net Climbs Up 62.71% In Jun`07 Qtr

For the quarterBiocon ended June 2007, Biocon exposed a fantastic increase in net profits.

USFDA Approves Lupin’s Novel Drug

The USFDALupin Pharmaceuticals has approved Lupin’s Abbreviated New Drug Application (ANDA)

Equity Churn Pushes Up Dabur Pharma

Dabur India LimitedIn early trade, Dabur Pharma was trading up 1.51% to Rs 77.50 after 50 lakh

Torrent Pharma Top Gainer at BSE

Torrent PharmaTorrent Pharma ascended 6.61% to Rs 257.95 and topped gainers in BSE’s ‘A’ group shares. The other gainers in the list were ABB, LIC Housing Finance, Reliance Energy and GMR Infrastructure.
Freshly, Torrent Pharma Ahmedabad based healthcare company had instigated Rimonabant, which is an anti-obesity molecule, for the first time in India under the trade name Rimoslim. The drug aims many cardio-metabolic risk factors that can lead to obesity, type 2 diabetes or dyslipidaemia.

Pages